Unlabelled: The PET compound (18)F-fluoroestradiol ((18)F-FES) has been developed and tested as an agent for the imaging of estrogen receptor (ER) expression in vivo. (18)F-FES uptake has been shown to correlate with ER expression assayed in vitro by radioligand binding; however, immunohistochemistry (IHC) rather than radioligand binding is used most often to measure ER expression in clinical practice. We therefore compared (18)F-FES uptake with ER expression assayed in vitro by IHC with both qualitative and semiquantitative measures.
Methods: Seventeen patients with primary or metastatic breast cancer were studied with dynamic (18)F-FES PET; cancer tissue samples, collected close to the time of imaging, were assayed for ER expression by IHC. For each tumor, partial-volume-corrected measures of (18)F-FES uptake were compared with ER expression measured by 3 different ER scoring methods: qualitative scoring (0-3+), the Allred score (0-10), and a computerized IHC index.
Results: There was excellent agreement (r = 0.99) between observers using IHC as well as the different methods of measuring ER content (P < 0.001). ER-negative tumors had (18)F-FES partial-volume-corrected standardized uptake values of less than 1.0, whereas ER-positive tumors had values above 1.1. Correlation coefficients for the different measures of ER content and the different measures of (18)F-FES uptake ranged from 0.57 to 0.73, with the best correlation being between the computerized IHC index and (18)F-FES partial-volume-corrected standardized uptake values.
Conclusion: Our results showed good agreement between (18)F-FES PET and ER expression measured by IHC. (18)F-FES imaging may be a useful tool for aiding in the assessment of ER status, especially in patients with multiple tumors or for tumors that are difficult to biopsy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2967/jnumed.107.047506 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Intratumoral Heterogeneity of Primary Breast Cancer on 18F-FES PET/CT and dbPET Anticipated a Heterogeneous Response to Chemotherapy.
Clin Nucl Med
January 2025
From the Department of Diagnostic Imaging and Nuclear Medicine, Graduate School of Medicine Kyoto University, Kyoto, Japan.
A 59-year-old woman with cT3N3M1 invasive breast cancer (ER low positive, PgR positive, HER2 negative) underwent PET/CT and dedicated breast PET scans using 18F-FDG and 18F-fluoroestradiol (18F-FES). While most primary tumor regions displayed low FES uptake, regions of high FES uptake were also identified. Following chemotherapy with the paclitaxel and bevacizumab, 18F-FDG PET/CT demonstrated a favorable response, but residual disease was noted in areas with high FES uptake on the pretreatment images.
View Article and Find Full Text PDFA Rare Case of Orbital Metastasis from Invasive Lobular Carcinoma: Challenges of F-FDG PET/CT and the Search for Consensus on Imaging.
J Nucl Med Technol
December 2024
Department of Radiology, University of Mississippi Medical Center, Jackson, Mississippi.
Invasive lobular carcinoma (ILC) frequently underlies orbital metastasis. A 74-y-old woman, who was current with mammograms and had no cancer history, presented to her ophthalmologist with visual complaints and was found to have metastatic ILC. MRI was contraindicated, and an F-FDG PET/CT scan revealed a mildly hypermetabolic right orbital mass and low uptake in the left subareolar breast, suggestive of metastatic ILC.
View Article and Find Full Text PDF[18F]-Fluoroestradiol (FES) brain PET in the evaluation of patients with estrogen receptor positive breast cancer and known or suspected brain metastases.
Eur J Radiol
December 2024
Weill Cornell Medicine, Department of Neurological Surgery, New York, NY, USA.
Objective: Our purpose was to describe our initial institutional experience using dedicated brain [18F]-Fluoroestradiol (FES) PET/CT or PET/MRI in the management of patients with estrogen-receptor-positive (ER+) breast cancer brain metastases (BCBM), and compare to [18F]-Fluorodeoxyglucose (FDG) PET and MRI.
Materials & Methods: Patients with biopsy-proven ER+ disease and MRI findings of suspected new, progressive, or recurrent BCBM were included in this retrospective study. Clinical and demographic data were collected.
A Single-Arm Phase II Clinical Trial of Fulvestrant Combined with Neoadjuvant Chemotherapy of ER+/HER2- Locally Advanced Breast Cancer: Integrated Analysis of 18F-FES PET-CT and Metabolites with Treatment Response.
Cancer Res Treat
January 2025
Department of Breast Cancer Center, Chongqing University Cancer Hospital, Chongqing, China.
Purpose: This Phase II trial was objected to evaluate the efficacy and safety of adding fulvestrant to neoadjuvant chemotherapy in patients with estrogen receptor (ER)+/human epidermal growth factor receptor 2 (HER2)- locally advanced breast cancer (LABC). Additionally, the study aimed to investigate the association of 16α-18F-fluoro-17β-fluoroestradiol (18F-FES) positron emission tomography (PET)-computed tomography (CT) and metabolites with efficacy.
Materials And Methods: Fulvestrant and EC-T regimen were given to ER+/HER2- LABC patients before surgery.
Dynamic whole-body [F]FES PET/CT increases lesion visibility in patients with metastatic breast cancer.
EJNMMI Res
March 2024
Department of Nuclear Medicine & PET-Centre, Aarhus University Hospital, Palle-Juul-Jensens Boulevard 165, 8200, Aarhus, Denmark.
Article Synopsis
- The correct identification of estrogen receptor (ER) status in breast cancer is crucial for effective treatment, but ER expression can vary within and between tumors, complicating diagnosis.
- A study utilizing dynamic whole-body (D-WB) [F]fluoroestradiol PET/CT in eight patients found that this technique provided better lesion visibility and quantitative data compared to traditional methods, with high correlations in measurements.
- The research concluded that D-WB [F]FES PET/CT is effective in accurately assessing ER status, potentially improving classification and treatment planning for metastatic ER-positive breast cancer patients.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!